Category: Clinical Trials / Drug Trials

A decline in physical function with age is strongly associated with disability in later life. Although regular exercise increases muscle strength and slows functional decline, the majority of elderly people are sedentary and either unwilling or unable to get adequate exercise. Alternative strategies to improve physical function are needed. Recent evidence suggests a potential role for angiotensin-converting-enzyme (ACE) inhibitors in improving muscle function in elderly people.

UCB, Inc. presented results from two Phase III pivotal trials and one open-label extension trial of rotigotine transdermal system for the treatment of moderate-to-severe restless legs syndrome (RLS). These rotigotine data showed significant drops in RLS symptoms, including changes of up to 8 points over placebo using the International Restless Legs Syndrome Study Group Rating Scale (IRLS) and a reduction in disease severity over a two-year period.

Medtronic, Inc. (NYSE:MDT) announced a synopsis of clinical data on the Endeavor? Drug Eluting Coronary Stent to be presented to an FDA Advisory Panel on October 10. This announcement was made in conjunction with the release of FDA Advisory Panel materials by the U.S. Food and Drug Administration and includes a pooled data analysis of the major trials encompassing the ENDEAVOR clinical program as well as newly released nine-month results from the ENDEAVOR IV clinical trial.

Medtronic, Inc. (NYSE:MDT) announced a synopsis of clinical data on the Endeavor? Drug Eluting Coronary Stent to be presented to an FDA Advisory Panel on October 10. This announcement was made in conjunction with the release of FDA Advisory Panel materials by the U.S. Food and Drug Administration and includes a pooled data analysis of the major trials encompassing the ENDEAVOR clinical program as well as newly released nine-month results from the ENDEAVOR IV clinical trial.

EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced that it has completed its Phase I clinical trial for EPC2407. The trial has met all of its objectives. EPC2407 is EpiCept’s novel small molecule vascular disruption agent (VDA) and apoptosis inducer for the treatment of patients with advanced solid tumors and lymphomas. EpiCept successfully identified the maximum tolerated dose of EPC2407 in the Phase I study.

CANCIDAS

Results from an extension to a Phase II study evaluating the effectiveness of Abbott’s investigational anti-IL-12/23 antibody ABT-874 showed that a majority of patients who initially responded to treatment maintained a high level of response following discontinuation of therapy. In the study, patients who achieved 75 percent improvement in psoriasis signs and symptoms (PASI 75) at 12 weeks stopped receiving ABT-874.

PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced encouraging data from a Phase 2 clinical trial of PTC124 in pediatric patients with cystic fibrosis (CF) due to a nonsense mutation.

Tokyo, Japan - Argenes, Inc. announce that it has started Phase I clinical study of the novel anti-rheumatoid arthritis (RA) agent ARG098 in patients with RA in Belgium and has administered to the first patient. The clinical study intends to evaluate the safety and tolerability of ARG098 into the knee joint cavity of patients with RA and examine its efficacy and pharmacokinetics.Efficacy of ARG098 on RA was found in the collaborative study with Santen Pharmaceutical Co., Ltd.

Centocor Inc, a subsidiary of drug company Johnson & Johnson have announced that international phase 3 trials for its injectable biologic drug to treat psoriasis, CNT0 1275 (ustekinumab), have shown promising results.According to the National Institutes of Health, some 7.5 million Americans have psoriasis, a non-contagious, lifelong skin disease.